Lenalidomide, a thalidomide derivative reduces proinflammatory cytokines, such as TNF-α, IL-1, IL-6, and IL-12 [85], and is being investigated in the MCLENA-1 Phase II trial to assess its efficacy in reducing neuroinflammation and cognitive decline in individuals with amnestic mild cognitive impairment (aMCI) due to AD (NCT04032626) [86]. This evidence concerns the gene IL1B and Alzheimer disease.